UNSPSC 51151669: Trospium chloride

This classification denotes an antimuscarinic agent with the molecular formula C25H30NO3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1E6682427E, chemically known as 6,10-ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate but generally known as trospium chloride, which bears US NIH Compound Identifier 107979. European Medicines Agency schedules Trospium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11349MIG.

Most nations schedule trospium chloride under HS 29399900 and SITC 54149. As of Q4 2014, TROSPIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Trospium chloride bears US NLM identifiers UMLS ID C0077408 and NCI Concept Code C61995. SMILES: Cl.O(C1CC2[N]3(C(CC2)C1)CCCC3)C(=O)C(O)(c1ccccc1)c1ccccc1.

UNSPSC 51151669 Trospium chloride is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities posted under this code show a significant mismatch with the code's nominal scope. The Seminole County, Florida solicitation (IFB60459723LAS) seeks naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission RFI (HHS0017013) explores direct-to-manufacturer prescription programs and pharmacy benefit management — neither of which involve trospium chloride procurement. The code shows little relevant recent activity aligned with its intended pharmaceutical product classification, suggesting either miscoding of opportunities by the issuing bodies or minimal actual procurement demand for this specific urological therapeutic agent at the state and local level.

The two opportunities on record originate from a state health agency (Texas HHS Commission) conducting preliminary market research and a county government (Seminole County, Florida) executing a competitive purchase. Geographic activity is limited to Florida and Texas based on available records. The Seminole County IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (note the inconsistent date stamp in the source), calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the Texas HHS RFI from April 3, 2026, remains exploratory and does not represent active procurement demand. No award amounts, vendor names, or set-aside designations appear in either record. Until state and local jurisdictions post opportunities that actually involve trospium chloride procurement, this code warrants monitoring rather than active pursuit.